Sirona Biochem Announces LOI for Collaboration with VitamFero

VANCOUVER, BRITISH COLUMBIA--(Marketwired - June 25, 2013) - Sirona Biochem Corp. (TSX VENTURE:SBM)(OTCQX:SRBCF)(FRANKFURT:ZSB) is pleased to announce the signing of a Letter of Intent (LOI) to create an extended collaboration with VitamFero. The goal of the collaboration is to apply Sirona Biochem's patented glycoprotein technology to the preservation of live attenuated animal vaccines.

"We are proud to be developing a partnership where our two unique technologies will be combined with the intent of advancing the science, economics and preservation capabilities of animal vaccines," said Neil Belenkie, CEO of Sirona Biochem.

"VitamFero is pleased to strengthen its partnership with Sirona Biochem. We are confident that strong synergies are to emerge from the extended collaboration that is going to be initiated," said Pascal Breton, CEO of VitamFero.

VitamFero develops live and attenuated animal vaccines against various infectious diseases, especially against Apicomplexa parasites. VitamFero intends to develop an effective protocol that, beyond their highly proven efficacy, extends the practicability of handling the anti-parasite vaccines. Further to the MTA signed in March 2013, VitamFero will evaluate Sirona Biochem's synthetic preservation technology to optimize its biopharmaceutical formulation and storage of its vaccine.

Using its proprietary chemistry technology, Sirona Biochem is developing biological preservation compounds to extend the life of stem cells, blood platelets, islets cells, tissues, organs and other biologics. By preserving these biologics, storage and transport times can be extended, such as in organ transplantation, thereby reducing or eliminating unnecessary disposal of valuable biological assets.

About VitamFero

VitamFero is a privately owned biotech company whose mission, founded on an innovative and patented technology (i.e. Toxo KO and Neo KO), is to create, develop, register and market novel anti-infectious vaccines, first against Apicomplexa parasites such as Toxoplasma gondii (toxoplasmosis agent), Neospora caninum (neosporosis agent) and Cryptosporidium parvum (cryptosporidiosis agent). With headquarters in Evry - Genopole^® (France) and laboratories in Tours (France), VitamFero is involved primarily in veterinary healthcare. For more information, visit: www.vitamfero.com.

About Sirona Biochem

Sirona Biochem is a biotechnology company developing diabetes therapeutics, skin depigmenting and anti-aging agents for cosmetic and pharmaceutical use, biological ingredients and cancer vaccine antigens. The company utilizes a proprietary chemistry technique to improve pharmaceutical properties of carbohydrate-based molecules. Sirona Biochem is the parent company of French-based biotechnology company TFChem. For more information visit: www.sironabiochem.com.

Sirona Biochem Corp also announces it has granted additional incentive stock options under its Stock Option Plan to directors and consultants exercisable for up to 700,000 shares of the Company. The options are exercisable on or before June 25, 2018 at an exercise price of $0.15 per share.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward- looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.